Literature DB >> 2572319

Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers.

M R Freeman1, R Washecka, L W Chung.   

Abstract

Amplification, rearrangement, or overexpression of the gene for the epidermal growth factor receptor (EGFR) occurs in certain types of human neoplasia. We investigated EGFR gene structure and measured EGFR mRNA levels in human renal tumor biopsies. Seventeen renal tumors [13 renal cell carcinomas (RCCs), two Wilms' tumors, one oncocytoma, and one metastatic ganglioneuroblastoma] and their corresponding normal kidney tissues were examined for EGFR gene structural integrity by Southern blot hybridization. Twelve of these tumors (including 11 RCCs) were examined for EGFR mRNA expression levels by RNA blot hybridization. The EGFR gene was rearranged in one of 13 (8%) of the RCC specimens examined and was highly amplified in the ganglioneuroblastoma. The overall frequency of EGFR gene structure alterations in this series of renal tumors was 12%. Nine of 11 RCC specimens (82%) exhibited markedly elevated EGFR mRNA levels (approximately 2- to 6-fold). In contrast, expression of the EGFR-related protooncogene HER-2 (erbB-2) was found to be decreased in 11 RCCs and one Wilms' tumor; HER-2 gene structure, however, appeared normal in all specimens. These results indicate that overexpression of EGFR mRNA, probably due to changes in gene regulation, and underexpression of HER-2 mRNA are characteristic features of human RCC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572319

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.

Authors:  M A Adelsman; B K Huntley; N J Maihle
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

2.  Induction of renal adenocarcinoma by a nonmutated erbB oncogene.

Authors:  C A Taglienti-Sian; B Banner; R J Davis; H L Robinson
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

3.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

4.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

5.  Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type.

Authors:  C D Gerharz; U Ramp; J Olert; R Moll; S Störkel; N Marx; H E Gabbert
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma.

Authors:  T Rasmuson; K Grankvist; B Ljungberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization.

Authors:  M J Stassar; G Devitt; M Brosius; L Rinnab; J Prang; T Schradin; J Simon; S Petersen; A Kopp-Schneider; M Zöller
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

8.  Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.

Authors:  R M Gemmill; M Zhou; L Costa; C Korch; R M Bukowski; H A Drabkin
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

9.  Transforming growth factor-alpha expression of renal proximal tubules in Wistar rats treated with ferric and aluminum nitrilotriacetate.

Authors:  J Deguchi; T Kawabata; A Kondo; S Okada
Journal:  Jpn J Cancer Res       Date:  1993-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.